Curasight Accelerates Clinical Trials for Five Cancer Indications

Curasight A/S, a clinical development company based in Copenhagen, Denmark, announced that it is accelerating and expanding its clinical treatment strategy by adding new Phase 1/2a trials covering five cancer symptoms in its so-called package—experimental design.

This trial tests uTRACE for brain cancer (glioblastoma), neuroendocrine cancer (NET), head and neck cancer (HNSCC), and non-neoplastic cancer (HNSCC) and Curasight. It will be investigated. Non-small cell lung cancer (NSCLC), pancreatic cancer. To strengthen the company's capital structure and secure funds to accelerate clinical work, Curasight plans to launch directly in the first quarter of 2024.

"We have a theranostic approach that uses radiopharmaceuticals to diagnose and treat certain types of cancer," he said. Ulrich Krasilnikoff, CEO of Curasight. “We achieved significant results in most indications with our platform, uTRACE, as well as first positive results in brain and lung cancer with our therapeutic solution, uTREAT. "By launching this trial package, we can simultaneously accelerate the development of uTRACE and uTREAT (treatment) and have treatment efficacy data by 2025." The parallel trials in five different types of cancer use a diagnostic platform that works across all tumor types because uPAR is expressed in most solid tumors. This increases the likelihood of partnerships with pharmaceutical companies.”

The Phase 1/2a test kit is part of Curasight's strategy to become a pharmaceutical leader in radiopharmaceuticals and diagnostics by combining better diagnostics with more targeted, simpler, and

The new study is an addition to Curasight's Phase 2 trial investigating uTRACE in prostate cancer as part of a collaborative contract with Curium Inc., with the first spatial data expected in the third quarter of 2024. Under the terms of the agreement, Curasight is responsible For development and regulatory approval, and Curium is accountable for manufacturing and commercialization. Curasight can earn up to US$70 during the development and commercial phases, including double-digit royalties on key market sales based on final sales.